Palo is done.

[anonymous]

Hey, what’s a billion dollars between friends?

 

[anonymous]

I guess it’s just a coincidence that pretty much everyone responsible for this dumpster fire of a deal-Meek, the psycho woman who used to run business development, Paulson, Graybill-managed to moonwalk out the door.

 

[anonymous]

One of the most remarkable deals I have ever seen and should be a black mark on anyone involved let alone the decision-makers. In its best light, it was pure negligence.

 

[anonymous]

One of the most remarkable deals I have ever seen and should be a black mark on anyone involved let alone the decision-makers. In its best light, it was pure negligence.

Does that include the 75% premium that was offered for the company right out of the gate when no one else was evening bidding or interested?

 

[anonymous]

Serious question: Who got a kickback from this deal?

 

[anonymous]

the "leadership team" called it a hiccup. That tells you all you need to know about who is pulling the levers here

 

[anonymous]

Peak global sakes of $50 million if we’re lucky. The deal payback should happen no later than 2050.

 

[anonymous]

Bring the crazy Slavic woman back to run business development.

 

[anonymous]

Exicure deal just went up in a puff of smoke. I thought this company was supposed to be getting better at business development?

 

[anonymous]

Exicure deal just went up in a puff of smoke. I thought this company was supposed to be getting better at business development?

At least they didn’t piss away a billion dollars and change on this like Clementia.

 

[anonymous]

Is palo selling a billion dollars a year yet? The clock is ticking.

 

[anonymous]

https://endpts.com/fda-rejects-ipsen-rare-disease-drug-more-data-and-time-needed-to-review/

 

[anonymous]

https://endpts.com/fda-rejects-ipsen-rare-disease-drug-more-data-and-time-needed-to-review/

I hate being right all the time.

 

[anonymous]

Ipsen's rare disease candidate rejected after mounting setbacks, delays

https://www.fiercebiotech.com/biote...ejected-after-facing-mounting-setbacks-delays

“The news marks the latest and greatest setback for palovarotene, which has faced a persistent uphill climb since Ipsen acquired the drug in its $1.31 billion purchase of Clementia Pharmaceuticals in 2019. Then-Ipsen CEO David Meek called the med “largely derisked,” evidently jinxing its future development path, which has been treacherous ever since.”

 

[anonymous]

Ipsen's rare disease candidate rejected after mounting setbacks, delays

https://www.fiercebiotech.com/biote...ejected-after-facing-mounting-setbacks-delays

“The news marks the latest and greatest setback for palovarotene, which has faced a persistent uphill climb since Ipsen acquired the drug in its $1.31 billion purchase of Clementia Pharmaceuticals in 2019. Then-Ipsen CEO David Meek called the med “largely derisked,” evidently jinxing its future development path, which has been treacherous ever since.”

DS in U.S. regulatory has f’d this up big time.

 

[anonymous]

DS in U.S. regulatory has f’d this up big time.

The fact that this drug had any chance after the PhIII readout is a regulatory miracle.

This is all on Meeks.

 

[anonymous]

The fact that this drug had any chance after the PhIII readout is a regulatory miracle.

This is all on Meeks.

Meek was an idiot. Everyone else who’s touched this thing since then has royally fucked up though.

 

[anonymous]

Are we a billion dollars yet?

 

[anonymous]

Are we a billion dollars yet?

Will you settle for $20 million?

 

[anonymous]

The fact that this drug had any chance after the PhIII readout is a regulatory miracle.

This is all on Meeks.

Regulatory is a train wreck.